SEC FORM 3

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Crouse Steven C.

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

55413

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President - Diag & Spatial Bi

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,894	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽²⁾	⁽²⁾	Common Stock	1,588	⁽¹⁾	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Common Stock	1,800	⁽¹⁾	D
Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Common Stock	1,379	⁽¹⁾	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	3,737	⁽¹⁾	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Common Stock	6,529	⁽¹⁾	D
Stock Option (right to buy)	⁽⁷⁾	04/01/2028	Common Stock	3,856	$97.13	D
Stock Option (right to buy)	⁽⁷⁾	08/06/2028	Common Stock	19,032	$120.46	D
Stock Option (right to buy)	⁽⁸⁾	08/15/2029	Common Stock	24,560	$94.52	D
Stock Option (right to buy)	⁽⁹⁾	08/15/2030	Common Stock	12,649	$84.61	D
Stock Option (right to buy)	⁽¹⁰⁾	05/01/2031	Common Stock	7,327	$73.46	D
Stock Option (right to buy)	⁽¹¹⁾	08/15/2034	Common Stock	17,133	$74.91	D
Stock Option (right to buy)	⁽¹²⁾	06/02/2035	Common Stock	5,434	$48.61	D
Stock Option (right to buy)	⁽¹³⁾	08/15/2035	Common Stock	19,151	$53.6	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.

3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.

4. 1,379 restricted stock units vest on 8/15/2026.

5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.

6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.

7. 100% vested.

8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney filed herewith.	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

New insider Crouse Steven C. claimed ownership of 5,894 shares (SEC Form 3)